A genetic-epigenetic interplay at 1q21.1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple
Majid Pahlevan Kakhki1, Antonino Giordano1,2,3,4, Chiara Starvaggi Cucuzza1,5
1Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Abstract:
Multiple Sclerosis (MS) is a heterogeneous inflammatory and neurodegenerative disease with an unpredictable course towards progressive disability. Treating progressive MS is challenging due to limited insights into the underlying mechanisms. We examined the molecular changes associated with primary progressive MS (PPMS) using a cross-tissue (blood and post-mortem brain) and multilayered data (genetic, epigenetic, transcriptomic) from independent cohorts. In PPMS, we found hypermethylation of the 1q21.1 locus, controlled by PPMS-specific genetic variations and influencing the expression of proximal genes (CHD1L, PRKAB2) in the brain. Evidence from reporter assay and CRISPR/dCas9 experiments supports a causal link between methylation and expression and correlation network analysis further implicates these genes in PPMS brain processes. Knock-down of CHD1L in human iPSC-derived neurons and knock-out of chd1l in zebrafish led to developmental and functional deficits of neurons. Thus, several lines of evidence suggest a distinct genetic-epigenetic-transcriptional interplay in the 1q21.1 locus potentially contributing to PPMS pathogenesis.
Insights
Researchers uncovered a genetic-epigenetic interplay in primary progressive multiple sclerosis (PPMS). This involves the 1q21.1 locus, impacting gene expression and potentially driving neurodegeneration in PPMS.
Area of Science:
- Neuroscience
- Genetics
- Epigenetics
Background:
- Multiple Sclerosis (MS) presents as a complex inflammatory and neurodegenerative condition with variable progression.
- Effective treatment for progressive MS forms remains difficult due to incomplete understanding of disease mechanisms.
Purpose of the Study:
- To investigate molecular alterations in primary progressive MS (PPMS) by analyzing genetic, epigenetic, and transcriptomic data across blood and brain tissues.
- To identify specific molecular pathways and genetic variations contributing to PPMS pathogenesis.
Main Methods:
- Utilized a multi-omics approach, integrating genetic, epigenetic (DNA methylation), and transcriptomic data from independent patient cohorts.
- Employed reporter assays and CRISPR/dCas9 gene editing to establish causal relationships between methylation and gene expression.
- Conducted gene knockdown in human neurons and knockout in zebrafish models to assess functional consequences.
Main Results:
- Identified hypermethylation at the 1q21.1 locus in PPMS, influenced by specific genetic variations.
- Demonstrated that this methylation pattern affects the expression of nearby genes, CHD1L and PRKAB2, in the brain.
- Confirmed a causal link between methylation and gene expression, implicating these genes in PPMS-related brain processes.
- Showcased that CHD1L deficiency leads to neuronal developmental and functional deficits.
Conclusions:
- A distinct genetic-epigenetic-transcriptional interaction at the 1q21.1 locus is suggested to play a role in the pathogenesis of PPMS.
- These findings provide novel insights into the molecular underpinnings of progressive MS, potentially opening avenues for targeted therapies.
More Related Videos
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Epigenetic Regulation
X-chromosome...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Incomplete Dominance
Genetic Lingo


